| Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy N Hanna, FA Shepherd, FV Fossella, JR Pereira, F De Marinis, ... Journal of clinical oncology 22 (9), 1589-1597, 2004 | 3079 | 2004 |
| First-line crizotinib versus chemotherapy in ALK-positive lung cancer BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ... N Engl j Med 371, 2167-2177, 2014 | 2327 | 2014 |
| Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC C Waldherr, M Pless, HR Maecke, T Schumacher, A Crazzolara, ... Journal of Nuclear Medicine 43 (5), 610-616, 2002 | 556 | 2002 |
| The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study C Waldherr, M Pless, HR Maecke, A Haldemann, J Mueller-Brand Annals of Oncology 12 (7), 941-945, 2001 | 440 | 2001 |
| Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non–small-cell lung cancer: a … DC Betticher, SF Hsu Schmitz, M Totsch, E Hansen, C Joss, C Von Briel, ... Journal of clinical oncology 21 (9), 1752-1759, 2003 | 431 | 2003 |
| A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer R Ramlau, E Quoix, J Rolski, M Pless, H Lena, E Lévy, M Krzakowski, ... Journal of Thoracic Oncology 3 (7), 735-744, 2008 | 192 | 2008 |
| Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study DC Betticher, SFH Schmitz, M Tötsch, E Hansen, C Joss, C Von Briel, ... British journal of cancer 94 (8), 1099-1106, 2006 | 190 | 2006 |
| Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial M Pless, R Stupp, HB Ris, RA Stahel, W Weder, S Thierstein, MA Gerard, ... The Lancet 386 (9998), 1049-1056, 2015 | 187 | 2015 |
| Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen‐specific immunotherapy in patients with MUC1‐positive advanced cancer C Rochlitz, R Figlin, P Squiban, M Salzberg, M Pless, R Herrmann, ... The Journal of Gene Medicine: A cross‐disciplinary journal for research on …, 2003 | 186 | 2003 |
| Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort J Mazieres, F Barlesi, T Filleron, B Besse, I Monnet, M Beau-Faller, ... Annals of Oncology 27 (2), 281-286, 2016 | 158 | 2016 |
| Prospective randomized comparison of thoracoscopic talc poudrage under local anesthesia versus bleomycin instillation for pleurodesis in malignant pleural effusions AH Diacon, C Wyser, CT Bolliger, M Tamm, M Pless, AP Perruchoud, ... American journal of respiratory and critical care medicine 162 (4), 1445-1449, 2000 | 145 | 2000 |
| Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial R Rosell, U Dafni, E Felip, A Curioni-Fontecedro, O Gautschi, S Peters, ... The Lancet Respiratory Medicine 5 (5), 435-444, 2017 | 134 | 2017 |
| Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial … T Ruhstaller, M Pless, D Dietrich, H Kranzbuehler, R von Moos, ... Journal of clinical oncology 29 (6), 626-631, 2011 | 124 | 2011 |
| Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 … C Mamot, D Klingbiel, F Hitz, C Renner, T Pabst, C Driessen, U Mey, ... Journal of clinical oncology 33 (23), 2523-2529, 2015 | 111 | 2015 |
| Outcome of treated advanced non-small cell lung cancer with and without central airway obstruction PN Chhajed, F Baty, M Pless, S Somandin, M Tamm, MH Brutsche Chest 130 (6), 1803-1807, 2006 | 99 | 2006 |
| Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial R Stupp, M Mayer, R Kann, W Weder, A Zouhair, DC Betticher, AD Roth, ... The lancet oncology 10 (8), 785-793, 2009 | 93 | 2009 |
| Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib … GA Pesce, D Klingbiel, K Ribi, A Zouhair, R Von Moos, M Schlaeppi, ... European journal of cancer 48 (3), 377-384, 2012 | 91 | 2012 |
| Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 … S Kubicka, R Greil, T André, J Bennouna, J Sastre, E Van Cutsem, ... Annals of oncology 24 (9), 2342-2349, 2013 | 82 | 2013 |
| Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using [90Y]-DOTA-D-Phe1-Tyr3-octreotide: a … C Waldherr, T Schumacher, M Pless, A Crazzolara, HR Maecke, ... Nuclear medicine communications 22 (6), 673-678, 2001 | 79 | 2001 |
| Influence of a nutritional intervention on dietary intake and quality of life in cancer patients: a randomized controlled trial A Uster, U Ruefenacht, M Ruehlin, M Pless, M Siano, M Haefner, ... Nutrition 29 (11-12), 1342-1349, 2013 | 77 | 2013 |
